Given that the majority of DLBCL patients with CD5/CD43 coexpression are older with a poor performance status and that the addition of rituximab to routine chemotherapy does not improve the outcomes of these patients, it will be important to better characterize this subset of DLBCL. Here, SPN is linked to diffuse large B-cell lymphoma.